Exelixis (EXEL) reported $2.3B in revenue for fiscal 2025, +7.0% year on year. That ranks #1252 by revenue among 2853 SEC filers and #112 in Healthcare. Net income was $783M, a net margin of 33.7%. Revenue has grown 16.0% a year on average since 2011 ($290M then). The fiscal 2025 balance sheet shows $2.8B in total assets, $482M in cash and $0 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $2.3B | +7.0% | FY20252026-01-02 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | $872M | +44.3% | FY20252026-01-02 |
| Net incomeNetIncomeLoss | $783M | +50.1% | FY20252026-01-02 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $884M | +26.3% | FY20252026-01-02 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $8.4M | −70.4% | FY20252026-01-02 |
| Total assetsAssets | $2.8B | −3.5% | FY20252026-01-02 |
| Shareholders' equityStockholdersEquity | $2.2B | −3.7% | FY20252026-01-02 |
| CashCashAndCashEquivalentsAtCarryingValue | $482M | +122.0% | FY20252026-01-02 |
| Long-term debtLongTermDebt | $0 | $0 | FY20172017-12-29 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-04-03 | $611M | $210M | Open → |
| Q2 20262026-07-03 | $629M | $212M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 5 of 161 companies compared | 33.7% | |
| Operating marginRank 7 of 160 companies compared | 37.6% | |
| R&D as share of revenueRank 10 of 102 companies compared | 35.6% | |
| Cash as share of revenueRank 51 of 160 companies compared | 20.8% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Exelixis, Inc.
- Ticker
- EXEL
- Exchange
- Nasdaq
- SIC classification
- Biological Products, (No Diagnostic Substances) (2836)
- Fiscal year end
- 01-01
- CIK
- 0000939767
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KFeb 10, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Aveanna HealthcareAVAH | $2.4B | $225,034 |
| Royalty PharmaRPRX | $2.4B | $771M |
| Hims & Hers HealthHIMS | $2.3B | $128M |
| ExelixisEXEL | $2.3B | $783M |
| NateraNTRA | $2.3B | −$208M |
| EnovisENOV | $2.2B | −$1.2B |
| Icu MedicalICUI | $2.2B | $732,000 |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Exelixis — Key figures |url=https://companiesranked.com/en/company/exelixis |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Exelixis — Key figures. CompaniesRanked. https://companiesranked.com/en/company/exelixisBibTeX
@misc{companiesranked-en-company-exelixis-2026,
author = {{CompaniesRanked}},
title = {{Exelixis — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/exelixis}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0000939767-26-000021 · February 10, 2026
{{cite web |title=Exelixis — Key figures — 10-K (0000939767-26-000021) |url=https://www.sec.gov/Archives/edgar/data/939767/000093976726000021/exel-20260102.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-10}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.